Clinical Features and Sera Anti-Aquaporin 4 Antibody Positivity in Patients with Demyelinating Disorders of the Central Nervous System from Tianjin, China-Reference-Cited by-同舟云学术

Clinical Features and Sera Anti-Aquaporin 4 Antibody Positivity in Patients with Demyelinating Disorders of the Central Nervous System from Tianjin, China

Published:2013-07-27 Issue:1 Volume:20 Page:32-39
ISSN:1755-5930
Container-title:CNS Neuroscience & Therapeutics
language:en
Short-container-title:CNS Neurosci Ther

Author:

Yang Chun-Sheng¹,Zhang Da-Qi¹,Wang Jing-Hua¹,Jin Wei-Na¹,Li Min-Shu¹,Liu Jie¹,Zhang Cun-Jin¹,Li Ting¹,Shi Fu-Dong¹²,Yang Li¹

Affiliation:

1. Department of Neurology and Tianjin Neurological Institute; Tianjin Medical University General Hospital; Tianjin China

2. Department of Neurology and Barrow Neurological Institute; St. Joseph's Hospital and Medical Center; Phoenix AZ USA

Publisher

Wiley

Subject

Pharmacology (medical),Physiology (medical),Psychiatry and Mental health,Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cns.12156/fullpdf

Reference33 articles.

1. Current and future treatment approaches for neuromyelitis optica;Collongues;Ther Adv Neurol Disord,2011

2. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel;Lennon;J Exp Med,2005

3. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica;Misu;Neurology,2005

4. Multiple sclerosis in the Japanese population;Kira;Lancet Neurol,2003

5. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: Nationwide survey results over 30 years;Osoegawa;Mult Scler,2009

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress in epidemiology, clinical features, and therapy of multiple sclerosis in China;Therapeutic Advances in Neurological Disorders;2023-01

2. The description of neuromyelitis optica spectrum disorder: Patient registry in Yangtze River Delta area of China;Multiple Sclerosis and Related Disorders;2022-10

3. Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments;Current Pharmaceutical Design;2022-02

4. The prevalence of anti-neurofascin-155 antibodies in patients with neuromyelitis optica spectrum disorders;Clinical and Experimental Immunology;2021-06-07

5. Elevated cerebrospinal fluid β2-microglobulin levels in patients with neuromyelitis optica spectrum disorders;Multiple Sclerosis and Related Disorders;2021-04